panitumumab,trifluridine,Tipiracil
amgen,taiho pharma
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)']
just out on "overall survival and subgroup analysis of the randomized phase ii velo trial" use of anti-egfri rechallenge in the continuum of care in ras/braf ctdna wt mcrc. #wcgic2023 
Oncologist, M.D. IEO, Division of Gastrointestinal and Neuroendocrine Tumors.